Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinoma.
Timeframe: 2022 – 2024 Goals: Advance immunotherapy for FLC by defining promising immunological targets that can be translated into effective cell-based immunotherapies Principal Investigators: Praveen Sethupathy, PhD (Cornell University); Mark Yarchoan, MD (Johns Hopkins University); Paul G. Thomas, PhD (St. Jude Children’s Research Hospital) Study overview: Like tumors of other cancer types, the microenvironment of …